[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eltrombopag\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eltrombopag":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100408629","phase-2-eltrombopag-for-chemotherapy-induced-thrombocytopenia-100408629",false,"NCT04600960","Eltrombopag for Chemotherapy-induced Thrombocytopenia","Eltrombopag for Chemotherapy-induced Thrombocytopenia: a Prospective Multi-center One-arm Study in Solid Tumors","Inclusion Criteria:\n\n* Aged ≥18 years old, male or female;\n* Conform to the diagnostic criteria of chemotherapy-induced thrombocytopenia (CIT); Ineffective after repeated treatment with rhTPO or IL-11；\n* Stop radiotherapy or chemotherapy for more than 1 month;\n* Platelet counts \\\u003C30 ×10\\^9\u002FL, and bleeding tendency;\n* Estimated survival period ≥ 6 months；\n* People who are willing to sign the informed consent voluntarily and follow the research program.\n* Liver and kidney function\\\u003C1.5×upper limit of normal, qualified for physical examination；\n* Subject is practicing an acceptable method of contraception. Women of childbearing potential must have a negative serum pregnancy test in the whole study;\n\nExclusion Criteria:\n\n* Those with uncontrollable primary diseases of important organs, such as extensive metastasis of malignant tumors, liver failure, heart failure, kidney failure and other diseases；\n* Patients with poor compliance;\n* Positive serology for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and\u002For hepatitis D virus (HDV), Syphilis; Positive for Epstein-Barr Virus DNA, Cytomegalovirus DNA;\n* Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal bleeding, intracranial hemorrhage, etc.\n* There is currently a heart disease requiring treatment or a poorly controlled hypertension judged by the investigator；\n* Patients with thrombotic diseases such as pulmonary embolism, thrombosis, and atherosclerosis；\n* Those who have received allogeneic stem cell transplantation or organ transplantation in the past；\n* Patients with mental disorders who cannot normally obtain informed consent and undergo trials and follow-up；\n* Patients whose toxic symptoms caused by treatment before participating in the trial have not disappeared；\n* Other serious diseases that may restrict participants from participating in this trial (such as diabetes; severe heart failure; myocardial obstruction or unstable arrhythmia or unstable angina in the past 6 months; gastric ulcers; mobility Autoimmune diseases, etc.)；\n* Patients with sepsis or patients with other irregular bleeding；\n* Patients taking antiplatelet drugs at the same time；\n* Pregnant women, suspected pregnancy (a positive pregnancy test for human chorionic gonadotropin in urine at screening) and breastfeeding patients；\n* Pre-existing cardiac disease, including congestive heart failure of New York Heart Association \\[NYHA\\] Grade III\u002FIV, arrhythmia requiring treatment or myocardial infarction within the last 6 months. No arrhythmia known to increase the risk of thrombotic events (e.g. atrial fibrillation), or patients with a QT \\>450msec or QTc \\> 480 for patients with a Bundle Branch Block;\n* Researchers believe that patients should not participate in the test of any other condition.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors",[26,27],"Chemotherapy-induced Thrombocytopenia","Eltrombopag","RECRUITING","2025-02-20",{"date":31,"type":32},"2025-02-24","ACTUAL",{"date":34,"type":32},"2020-12-31",{"date":36,"type":20},"2025-12-31",{"name":38,"class":39},"Institute of Hematology & Blood Diseases Hospital, China","OTHER"]